Daiichi Sankyo's Turalio, or pexidartinib, received FDA approval as a treatment for adults with tenosynovial giant cell tumor, a rare, non-cancerous tumor that affects a patient's joints and limbs. A boxed warning is included in its label warning of the potential risk for serious and possibly fatal liver injury.
FDA OKs pexidartinib to treat tenosynovial giant cell tumor
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.